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1. Introduction
Asthma is a major public health problem with a 
huge social and economic burden affecting 300 million 
people worldwide. It is the most common chronic respi-
ratory disease, affecting up to 10 % of the adults and 
30 % of the children in the Western world [1]. 
Asthma is a chronic, heterogeneous disease with 
symptoms and features that include wheeze, cough 
(particularly at night and during exertion), dyspnoea and 
chest tightness, variable airways obstruction and bron-
chial hyperresponsiveness. The underlying chronic in-
flammation is often characterised by eosinophilic activ-
ity and allergic inflammation, and airways remodelling 
is a frequent feature of asthma, even in young children, 
although not in the very early stages. The longer-term 
risks for the patient with poor control include asthma 
attacks, impaired development or accelerated decline in 
lung function, and side-effects of treatment. Despite the 
availability of effective medication, many children do not 
have adequately controlled asthma. This has implications 
for quality of life (QoL) and daily physical activity, and 
clearly increases the burden of disease in terms of costs 
to the family and society. 
2. Case presentation
Children with asthma frequently report limita-
tions in activities and sports (reported in ≤ 47 % of chil-
dren with asthma), nocturnal awakening due to asthma 
(≤ 34 %) and absence from school (≤51 %) [2].
At least 10–12 % of patients with bronchial asth-
ma (BA) suffer from severe phenotype of the disease [3], 
at the same time relatively small proportion of patients 
with refractory severe BA to the treatment accumulates 
40–50 % of health care resources among the total pop-
ulation of patients with BA, causing a disproportionate 
large share of health facilities expenses [4]. Severe 
asthma is singled out into a separate phenotype and 
requires aggressive therapeutic approaches to achieve 
control [5, 6].
A major part of the burden of disease is caused by 
acute exacerbation in general practice and emergency 
department in the hospitals. Despite advances in asthma 
management, acute exacerbation continues to occur and 
impose considerable morbidity on patients and constitute 
a major burden on health care resources [7, 8].
An increasing prevalence of pediatric asthma has 
led to increasing burdens of critical illness in children 
with severe acute asthma exacerbations, often leading to 
respiratory distress, progressive hypoxia, and respiratory 
failure [9, 10]. Exacerbations can be defined as the pres-
ence of either one of the following signs and symptoms of 
airflow obstruction within the past 48 hours (e. g. cough, 
wheezing, shortness of breath and chest tightness) and 
repeated use of short-acting beta-agonists within the past 
48 hours [1].
Early treatment of asthma exacerbations is the 
best strategy for management. Important elements of 
early treatment at the patient’s home include a written 
asthma action plan; recognition of early signs and symp-
toms of worsening; appropriate intensification of therapy 
by increasing short-acting β-agonists and, in some cases, 
adding a short course of oral corticosteroids; removal, or 
withdrawal from an environmental factor contributing to 
the exacerbation; and prompt communication between 
the patient and clinician, seeking emergency care for 
severe manifestations, or both. Despite adherence to op-
timal chronic asthma care, it is increasingly recognized 
that some patients will require an urgent office visit or 
even an emergency department (ED) visit for further 
asthma care [11].
3. Aim of research
Improving relieving treatment of bronchial asthma 
attacks in children of school age with a severe phenotype 
of the disease.
4. Material and methods
Keeping the bioethics principles on the base of 
pulmonological department of the Regional Pediatric 
Hospital (Chernivtsi) 57 school-age children with se-
vere persistent asthma were examined. Diagnosis of the 
disease was verified according to the BA classification 
[12, 13], the attack period was determined in 48 patients 
(84,2 %). The proportion of boys reached 59,6 %, inhabi-
tants of the rural area made up 61,4 %, the average age of 
school children reached 12,6±0,43 years.
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The severity of bronchial obstruction syndrome 
(BOS) on patients’ admission to the hospital during the 
exacerbation period was assessed by point scale [14], and 
intensification of BOS manifestations was reflected in 
the increasing of the total amount of points on this scale.
Therapeutic tactics in the period of attack was 
assigned according to the protocol for diagnosis and 
treatment of asthma in children approved by GINA rec-
ommendations in 2014 versions [15] and “Guidelines for 
BA diagnosis and treatment in children” – PRACTALL 
[16]. In accordance with these documents for the purpose 
of desobstruction short-acting β2-agonists, glucocortico-
steroids (GCS) of systemic effect (1–3 mg/kg for 1 ad-
ministration for prednisolone, but not more than 60 mg 
per day intravenously) and methylxanthines preparations 
(Euphylline 3–5 mg/kg for 1 administration, but not more 
than 200 mg per day intravenously) were used. 
In assessing the probability of the indexes dif-
ference Student’s coefficient (t) was calculated. For a 
probable difference, the index at p<0,05 was taken. In 
assessing relative indixes, Fisher’s exact criterion (pφ) 
was used. The results were analyzed using the principles 
of clinical epidemiology. Risk of event realization was 
evaluated taking into account the probability of relative 
risks (RR), attributive risks (AR) and odds ratios (OR), 
as well as the assessment of their 95 % of confidence in-
tervals. The effectiveness of the treatment was evaluated 
in terms of reduce of absolute risk (RAR) and relative 
risk (RRR) specifying a minimum number of patients 
who should be treated in order to gain one positive result 
(number of patients to be treated, NNT) [17].
5. Results 
It was determined that in patients with severe BA 
for the purpose of desobstruction short-acting inhalation 
β2-agonists, GCS of systemic effect and methylxanthines 
preparations (Euphylline) were administered for oral and 
intravenous use in various combinations with one another. 
Thus, monotherapy with short-acting inhalation β2-ago-
nists (salbutamol) and in combination with theophylline 
per os was used in 19,6 % of cases, addition of cortico-
steroids of systemic effect to the previous version – in 
17,7 % of patients. It was also noticed that every second 
child (52,9 %) with severe BA for the purpose of effective 
bronchodilatation needed combined use of all three groups 
of desobstructive therapeutic means. That is, 80,0 % of 
children with severe BA received GCS of systemic effect, 
the average duration of the course was 2,9±0,19 days. A 
quarter of schoolchildren (26,8 %) received the course of 
GCS of systemic effect, exceeding 3 days.
Most pupils with severe BA (52,9 %) in acute peri-
od of the disease received infusion therapy with methylx-
anthines (Euphylline), the average duration of infusion 
therapy in children with severe pathology persistence 
lasted 3,3±0,24 days. 44,4 % of patients received infusion 
therapy more than 3 days.
The Table 1 demonstrates the assessment indices of 
the attack severity in children with severe BA when GCS 
of systemic effect were used during three days, compared 
with one- and two-day course of their application.
Table 1
Risk indices of attack severity regression at  
a 3-day administration of glucocorticosteroids of 
systemic effect in children with severe bronchial asthma 
compared to one- and two-day course
Point assessment 









On the third day of 
hospital treatment – 







On the seventh day of 
hospital treatment – 







These data corroborate that the three-day course 
of GCS of systemic effect compared with a shorter term 
of their administration was characterized by a probable 
regress risk of point assessment of the attack severity on 
the seventh day of hospital treatment.
Against the background of relieving treatment 
with GCS of systemic effect during 3 days the attack 
severity regress was also observed on the seventh day of 
hospitalization compared to the first day, in particular the 
pronounced manifestations of BOS (over 12 points) before 
treatment were observed in 83 % of schoolchildren, at 
the end of the treatment the assessment of bronchial ob-
struction severity of more than 6 points occurred only in 
16,2 % of cases (pφ<0,05). Thus, the RRR of preserving 
severe bronchial obstruction reached 80 %, the RAR was 
67 % with the number of patients to be treated – 1,5 against 
the background of the three-day therapeutic course with 
GCS of systemic effect in children of the I clinical group 
on the seventh day of hospital treatment.
Intravenous Euphylline application in combina-
tion with GCS, short-acting inhalation β2-agonists com-
pared to therapy with steroids, short-acting inhalation 
β2-adrenomimetics in children was associated with the 
risk of attack severity decrease on the third and seventh 
day of hospital treatment (Table 2). 
Table 2
Indices of the risk of attack severity decrease against the 
background of intravenous Euphylline application in 
children
Regress of point assessment 
of BA severity attack
Risk indices




on the third day of hospital 
treatment –  
more than 3 points
0,32 1,8 (0,9–3,5) 4,0 (1,2–12,4)
on the seventh day of hospi-
tal treatment –  
more than 9 points
0,20 1,4 (0,8–2,7) 2,3 (0,7–7,6)
Note: AR – absolute risk
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The received data give reason to consider the risk 
indices of BA attack severity decrease convincing against 
the background of intravenous Euphylline administration 
in children with severe variant of the disease on the third 
day of hospital treatment. Under the influence of the 
mentioned treatment among the children of both clinical 
groups the proportion of patients with severe bronchial 
obstruction decreased; the obstruction was estimated by 
more than 12 points on the first day of hospital treatment 
and by more than 6 points on the seventh day of hospi-
talization (85 % and 22 % respectively, pφ<0,05). Thus, 
the RRR of severe bronchial obstruction on the seventh 
day of hospitalization in patients with severe BA reached 
74 %, RAR was 63 % with the number of patients to be 
treated – 1,5.
6. Discussion
Since the basis of asthma is inflammation of the 
airways, it is a major target of anti-asthmatic treatment 
[18], and glucocorticosteroids are the “cornerstone” of 
both achieving and retaining control in patients with 
persistence of the disease and a major component of the 
relieving therapy [19]. This assumption was confirmed 
by the study, when the lion’s share of children (80.0 %) 
suffering from a severe disease phenotype, received 
system glucocorticosteroids in the period of attacks. It is 
noteworthy that the duration of use of these drugs with 
a positive delayed effect on the VIIth day of treatment 
was 3 days. 
The use of theophylline derivatives to relieve 
pain remains disputable. The results of recent studies 
have allowed to justify the use of these drugs in case 
of severe asthma not only as bronchodilators, but also 
as remedies with anti-inflammatory effect that pre-
vent bronchial remodeling [20]. The anti-inflammatory 
effect, in addition to inhibition of phosphodiesterase 
activity and adenosine receptor blockade, is imple-
mented by activating histone deacetylase, reducing the 
concentration of IL-8 and enhancing apoptotic neutro-
phils properties, as evidenced by their reduction in the 
induced sputum [21]. In small doses, the theophylline 
drugs enhance the anti-inflammatory effects of gluco-
corticosteroids [22]. The combination of bronchodilator 
and anti-inflammatory effects might have allowed ob-
taining both a quick relieving effect on the third day of 
treatment and preservation of the bronchodilator action 
on day seventh day of hospitalization.
At the same time, since it was eosinophils which 
were targeted by the impact of glucocorticosteroids, and 
methylxanthines are characterized by some pro-apop-
totic effect on neutrophils, it would be appropriate to 
discretely analyze their effectiveness in different groups 
of children depending on the nature of airway inflam-
mation. 
7. Conclusion
1. The patients with severe BA for the purpose of 
bronchial relief were administered short-acting inhala-
tion β2-agonists, GCS of systemic effect and methylxan-
thines preparations (Euphylline).
2. The three-day course of steroids of systemic 
effect compared with a shorter term of their administra-
tion was characterized by a probable regress risk of point 
assessment of the attack severity on the seventh day of 
treatment.
3. Intravenous Euphylline application in combi-
nation with systemic steroids, short-acting inhalation 
β2-agonists in children was associated with the risk of 
attack severity decrease on the third and seventh day of 
treatment. 
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